Cellectar Reports Financial Results for the Second Quarter 2021 and Provides a Corporate Update Aug 9, 2021
Cellectar Announces a Co-Development and Commercialization Collaboration with LegoChemBio for New Small Molecule Phospholipid Drug Conjugates (PDCs) Jul 12, 2021
Cellectar Announces the Election of Dr. Asher Alban Chanan-Khan to Its Board of Directors Jun 24, 2021
Cellectar Presents Data in Waldenstrom’s Macroglobulinemia in Poster at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Jun 4, 2021
Cellectar Announces Poster Presentation of CLR 131 Data in Waldenstrom’s Macroglobulinemia at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting May 20, 2021
Cellectar to Participate at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021 May 14, 2021
Cellectar Reports Financial Results for the First Quarter 2021 and Provides a Corporate Update May 10, 2021
Cellectar Strengthens Global IP Position with Phospholipid Drug Conjugate Composition of Matter Patent in Eurasia, Australia, and Mexico Apr 27, 2021
